Literature DB >> 30348671

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Lauren C Chong1, Susana Ben-Neriah1, Graham W Slack1, Ciara Freeman1, Daisuke Ennishi1, Anja Mottok2, Brett Collinge1, Pau Abrisqueta3, Pedro Farinha1, Merrill Boyle1, Barbara Meissner1, Robert Kridel4, Alina S Gerrie1, Diego Villa1, Kerry J Savage1, Laurie H Sehn1, Reiner Siebert2, Ryan D Morin5,6, Randy D Gascoyne1, Marco A Marra6, Joseph M Connors1, Andrew J Mungall6, Christian Steidl1, David W Scott1.   

Abstract

Genomic rearrangements in the MYC locus occur in ∼12% of lymphomas with diffuse large B-cell lymphoma (DLBCL) morphology and are associated with inferior outcome. Previous studies exploring MYC rearrangements have primarily used fluorescence in situ hybridization (FISH) assays to characterize break-apart status but have rarely examined breakpoint location, and in some cases have not examined partner identity. We performed targeted sequencing of MYC, BCL2, BCL6, and the immunoglobulin (IG) loci in 112 tumors with DLBCL morphology harboring MYC rearrangement. We characterized the location of the MYC rearrangement at base pair resolution and identified the partner in 88 cases. We observed a cluster of breakpoints upstream of the MYC coding region and in intron 1 (the "genic cluster"). Genic cluster rearrangements were enriched for translocations involving IGH (80%), whereas nongenic rearrangements occurred mostly downstream of the MYC gene with a variety of partners, including IGL and IGK Other recurrent partners included BCL6, ZCCHC7, and RFTN1, which has not previously been described as a MYC partner. We compared 2 commercially available FISH break-apart assays for the MYC locus and observed discordant results in 32% of cases examined, including some with MYC-IGL and MYC-IGK rearrangements. In cases of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement (HGBL-DH), so-called "double-hit" lymphomas, the majority of MYC rearrangements had non-IG partners (65%), with breakpoints outside the genic cluster (72%). In patients with de novo HGBL-DH of DLBCL morphology, MYC-IG rearrangements showed a trend toward inferior time to progression and overall survival compared with MYC-non-IG rearrangements. Our data reveal clinically relevant architecture of MYC rearrangements in lymphomas with DLBCL morphology.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30348671      PMCID: PMC6199666          DOI: 10.1182/bloodadvances.2018023572

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  48 in total

1.  Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma.

Authors:  Sonia Fabris; Clelia Tiziana Storlazzi; Luca Baldini; Lucia Nobili; Luigia Lombardi; Anna Teresa Maiolo; Mariano Rocchi; Antonino Neri
Journal:  Genes Chromosomes Cancer       Date:  2003-07       Impact factor: 5.006

2.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.

Authors:  David W Scott; George W Wright; P Mickey Williams; Chih-Jian Lih; William Walsh; Elaine S Jaffe; Andreas Rosenwald; Elias Campo; Wing C Chan; Joseph M Connors; Erlend B Smeland; Anja Mottok; Rita M Braziel; German Ott; Jan Delabie; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Timothy C Greiner; Betty J Glinsmann-Gibson; Kai Fu; Louis M Staudt; Randy D Gascoyne; Lisa M Rimsza
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

3.  Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas.

Authors:  L Zech; U Haglund; K Nilsson; G Klein
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

Review 4.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 5.  How I treat double-hit lymphoma.

Authors:  Jonathan W Friedberg
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

6.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

7.  Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.

Authors:  R Taub; I Kirsch; C Morton; G Lenoir; D Swan; S Tronick; S Aaronson; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

8.  ''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases.

Authors:  Olga K Weinberg; Weiyun Z Ai; M Rajan Mariappan; Carol Shum; Ronald Levy; Daniel A Arber
Journal:  J Mol Diagn       Date:  2007-07-25       Impact factor: 5.568

9.  Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t(8;14) translocations in sporadic Burkitt-lymphoma.

Authors:  K Busch; T Keller; U Fuchs; R-F Yeh; J Harbott; I Klose; J Wiemels; A Novosel; A Reiter; A Borkhardt
Journal:  Leukemia       Date:  2007-05-31       Impact factor: 11.528

10.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.

Authors:  B A Walker; C P Wardell; A Brioli; E Boyle; M F Kaiser; D B Begum; N B Dahir; D C Johnson; F M Ross; F E Davies; G J Morgan
Journal:  Blood Cancer J       Date:  2014-03-14       Impact factor: 11.037

View more
  19 in total

Review 1.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

2.  Molecular Risk Stratification in Aggressive B-Cell Lymphomas.

Authors:  Zachary A K Frosch; Daniel J Landsburg
Journal:  J Clin Oncol       Date:  2020-04-02       Impact factor: 44.544

Review 3.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

4.  Comparison Between Integrated Genomic DNA/RNA Profiling and Fluorescence In Situ Hybridization in the Detection of MYC, BCL-2, and BCL-6 Gene Rearrangements in Large B-Cell Lymphomas.

Authors:  Daniel P Cassidy; Jennifer R Chapman; Rafael Lopez; Kyle White; Yao-Shan Fan; Carmen Casas; Eric A Severson; Francisco Vega
Journal:  Am J Clin Pathol       Date:  2020-02-08       Impact factor: 2.493

5.  The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.

Authors:  Laura K Hilton; Jeffrey Tang; Susana Ben-Neriah; Miguel Alcaide; Aixiang Jiang; Bruno M Grande; Christopher K Rushton; Merrill Boyle; Barbara Meissner; David W Scott; Ryan D Morin
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

6.  Coexistence of MYC/BCL2 double-hit of t(8;14)(q24;q32) and t(14;18)(q32;q21) and that of t(8;22)(q24;q11) and t(14;18) in advanced-stage high-grade B cell lymphoma.

Authors:  Kayo Takeoka; Miho Nakagawa; Chiyuki Kishimori; Katsuhiro Fukutsuka; Fumiyo Maekawa; Masahiko Hayashida; Hitoshi Ohno
Journal:  Ann Hematol       Date:  2020-09-07       Impact factor: 3.673

Review 7.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

8.  Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.

Authors:  Leo Meriranta; Annika Pasanen; Amjad Alkodsi; Jari Haukka; Marja-Liisa Karjalainen-Lindsberg; Sirpa Leppä
Journal:  Blood Adv       Date:  2020-08-11

9.  Histone acetylation dynamics modulates chromatin conformation and allele-specific interactions at oncogenic loci.

Authors:  Stephanie Sungalee; Yuanlong Liu; Ruxandra A Lambuta; Natalya Katanayeva; Maria Donaldson Collier; Daniele Tavernari; Sandrine Roulland; Giovanni Ciriello; Elisa Oricchio
Journal:  Nat Genet       Date:  2021-05-10       Impact factor: 38.330

10.  The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.

Authors:  Neeraj Sharma; James B Smadbeck; Nadine Abdallah; Cinthya Zepeda-Mendoza; Moritz Binder; Kathryn E Pearce; Yan W Asmann; Jess F Peterson; Rhett P Ketterling; Patricia T Greipp; P Leif Bergsagel; S Vincent Rajkumar; Shaji K Kumar; Linda B Baughn
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.